Related coverage linked through entity extraction aliases.
Jul 10, 2026
Study links MMR hesitancy to right-leaning media and alternative health sources. As US measles cases top 2,000, New Jersey confirms its first case of the year and urges vaccination.
Jun 15, 2026
FDA reinstates top vaccines regulator ten days after abrupt departure, drawing criticism from public health experts and far-right commentators. Departure was tied to Duchenne muscular dystrophy treatment and COVID-19 vaccine controversies.
Aug 01, 2026
New studies show rapid expansion of ADHD drug prescribing, with US youth psychiatric drug use rising from 5.3% to 8.3% and Ontario stimulant prescriptions surging 175% during COVID.
Aug 08, 2026
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
May 07, 2026
MARGO, BIOPREVENT, and FOCaL are new machine-learning frameworks for adaptive clinical trial randomization, post-transplant risk prediction, and personalized treatment effects. Each showed improved performance over conventional methods.
Aug 02, 2026
Moderna reported a second-quarter loss of $782 million and a first-quarter loss of $1.34 billion, both beating expectations. The company appointed a new Chief Commercial Officer ahead of vaccine launches and disclosed CFO restricted stock unit transactions.
Jul 08, 2026
CDC suppressed COVID-19 vaccine data; federal agencies may remove vaccines from the US market. Clinicians cite a JAMA study: 40% efficacy against hospitalization, 79% against severe outcomes.
Jul 25, 2026
The FDA has refused to file Moderna's flu vaccine candidate mRNA-1010. The company will push forward outside the U.S. and pause its combination flu vaccine, while expressing disappointment over the decision's regulatory implications.
Jul 21, 2026
BioNTech reported a Q1 2026 net loss of $622.3 million as revenue declined to $138.0 million and R&D spending rose to $651.6 million. The company expanded its oncology pipeline with five new pivotal trials for pumitamig and announced manufacturing site exits to save $584.9 million annually by 2029.
Jul 17, 2026
Laboratory monkey prices in China have surged to as much as 180,000 yuan, exceeding average wages, as booming drug research drives demand beyond limited supply. Researchers report that colonies are fully pre-booked, forcing some studies to halt. Supply-demand imbalance is forecast to persist, leading to further price increases.
Jul 16, 2026
Moderna awaits an August 2026 FDA decision on its mRNA flu vaccine while expanding into oncology, autoimmune disease, and monkeypox. Its COVID-19 vaccine Spikevax remains central amid financial losses and cautious analyst sentiment.
Jul 14, 2026
Six-year SEQUOIA trial data show zanubrutinib sustains a progression-free survival advantage (74% vs 32%) over bendamustine-rituximab in CLL without del(17p). Benefit extends to high-risk del(17p) patients.
Jun 26, 2026
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
Jun 25, 2026
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Jun 25, 2026
University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
Jun 11, 2026
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
Jun 11, 2026
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Jun 06, 2026
Long COVID patients continue to suffer as federal research funding and support programs have been dramatically scaled back, with the Office of Long COVID Research and Practice closed and NIH grants disrupted. The chronic condition affects as many as a third of COVID-19 survivors with over 200 possible symptoms, yet experts say the disease remains difficult to research amid politicization. Medical professionals warn that reduced resources undermine diagnosis, treatment, and the professional pipeline for new research.
Jun 03, 2026
A large international study published in eClinicalMedicine found that COVID-19 booster vaccination was tied to a 33% lower risk of preeclampsia in pregnant women across 18 countries. Getting COVID during pregnancy increased preeclampsia risk by 78% in unvaccinated women, but vaccination with a booster reduced those odds significantly.
Jun 01, 2026
The FDA has approved Shionogi's XOCOVA (ensitrelvir) as the first oral antiviral for post-exposure prophylaxis of COVID-19. Approval was based on the Phase 3 SCORPIO-PEP trial, which showed a 67% reduction in risk of symptomatic disease after exposure.
